- Guys, Take the Lead in Self-Checks for Testicular Cancer
- Re-focusing on Getting Fit? Heart Experts Offer These Tips
- AHA News: Not Just Bad Shoes and Sore Muscles – She Had Peripheral Artery Disease
- Scientists Find Clues to Why AstraZeneca’s Vaccine May Cause Clots
- Stressed, Exhausted: Frontline Workers Faced Big Mental Strain in Pandemic
- Supply of J&J COVID Vaccine to Drop 86 Percent Next Week
- Health Highlights: April 9, 2021
- Nearly Half of U.S. Veterans Cited ‘Personal Growth’ During Pandemic: Survey
- Bright Side: Sunnier Areas Have Lower COVID-19 Death Rates
- Pandemic Has Put Many Clinical Trials on Hold
Tretten Approved for Genetic Clotting Disorder
Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.
People with the genetic disorder do not make enough Factor XIII, a blood component that promotes clotting. Tretten, a human recombinant produced in yeast cells, makes up for this deficiency, which could otherwise be life threatening, the FDA said Monday in a news release.
Tretten was evaluated in a clinical study of 77 people with the disorder. Administered monthly, it was effective in preventing bleeding in 90 percent of recipients. Side effects included headache, extremity pain and pain at the injection site. No study participant developed abnormal clotting, the FDA said.
The product was developed and is produced by Novo Nordisk, based in Denmark.
More information
To learn more about this disorder, visit the National Hemophilia Foundation.
Source: HealthDay
